Apontis Pharma: Course jumps after positive comments

After three quarters, Apontis Pharma’s sales increased by 17. percent to 3.1 million euros. EBITDA rises slightly to 1.7 million euros in the third quarter. The turnover for the whole year is estimated at 55.5 million euros. This is confirmed by the Montega Connect virtual conference. The fourth quarter should therefore be quite weak. If the forecast comes true, sales are likely to drop by about 1 percent. Apontis Pharma plans to announce two licensing partnerships in the single pill business soon. The corresponding contracts were signed this week. Two more contracts are in final negotiations. In fact, the plan is to launch 17 individual pills in 202 . However, according to currently known plans, this could be achieved as early as 2023. Analysts Affirm Buy Recommendation on Shares of Apontis Pharma (WKN: A3CMGM, ISIN: DE000A3CMGM5, Chart). The target price is still 26.00 euros. analysts praised the pipeline expansion. This should have a positive impact on profitability from 202 onwards. The year 2023, on the other hand, is a transition period. According to analysts, the current valuation does not seem justified. They expect earnings per share to be €0.25 in 2022, €0.05 in 2023, before rising to €0.50 in 202 .

James Rogers

Learn More →

Dodaj komentarz

Twój adres e-mail nie zostanie opublikowany.